One question we hear regularly from emerging biotechs is: Do we really need a formal Target Product Profile right now?
Like many good answers to regulatory questions, “it depends.” A great TPP that is grounded in data and strategy and brings you credibility with investors and partners will cost time and capital.
A formal TPP process applied without calibration to your resources and stage will not serve a nimble emerging biotech company well. This is not a criticism of the tool. It’s a recognition that emerging biotechs have to do more with less, and to thrive, small companies have to know which tools to leverage and when.
The question is not whether to have a TPP, but what form of strategic clarity is appropriate for where you are right now.
What Is a Target Product Profile (TPP)?
Anyone who has worked in large pharma is familiar with a Target Product Profile, or TPP. It’s a strategic document that defines the desired characteristics of your product, including the intended indication(s), efficacy benchmarks, safety tolerances, dosing, route(s) of administration, and commercial positioning.
A well-structured TPP typically contains:
- A minimally acceptable profile
- An upside (ideal) profile
- The key product attributes from the mechanism(s) of action and patient population(s) to comparator benchmarks and health-economics assumptions
In short, it’s the company’s formal hypothesis about the product you are trying to develop and the benchmarks against which you will determine whether that product is worth continued development resources.
For large pharma, the TPP is the gold standard. TPPs are generated for every product, and their development involves teams of regulatory strategists, health economists, physicians, and business analysts. However, what works for large pharma doesn’t always translate to emerging biotech.
When a TPP Helps an Emerging Biotech and When It Hurts
Without a written record of what success looks like, programs can drift: the CMC lead optimizes for manufacturability, the clinical lead designs endpoints around a different patient subgroup, and the commercial lead has been talking to payers about an indication that was quietly abandoned two months ago. Misalignment often surfaces only after time and capital have already been lost.
A company must clearly articulate what their asset needs to demonstrate to be approvable and commercially viable. It is essential to attract interested partners and get investment. When it comes to FDA dialogue, the TPP can also signal company sophistication and regulatory maturity. While a TPP is not required, the FDA is familiar with the TPP format (they even have guidance on it!) and appreciates it as a tool to help focus productive development conversations.
However, preparing a data-driven TPP too early can waste resources that a small company cannot afford. In discovery and pre-IND, the data required to write a TPP (e.g., competitive landscape, PK/PD models, tox signals, patient stratification, etc.) may not exist or, at best, are incomplete. Companies that try to force a grand TPP too early often spend $50,000-$200,000 preparing and maintaining a document that will be revised five times before a single patient is dosed.
Once a TPP is circulated to investors and embedded in board presentations, there is real pull for organizations to defend it. When real data suggests a different dose, patient population, endpoint, or even indication, revising the TPP can feel like admitting failure or look like uncertainty, even when it’s exactly the right scientific move.
Although the emerging biotechs and device companies rarely fall squarely into the identified stages of development, the stages serve as a way to think about when a TPP might be right.
How Emerging Biotech Companies Should Use a TPP by Stage
A well-timed TPP has the advantage of forcing cross-functional conversations that small teams sometimes skip. It creates a shared language across biology, clinical, regulatory, manufacturing, and business development. In emerging companies, it’s not unusual for two people to be wearing all five hats, but it’s also not unusual for some of these roles to be held by consultants.
Let’s uncover what makes sense at each critical juncture, considering development stage, resources, and operational bandwidth.
Discovery and pre-IND:
What you need here is a lean hypothesis document, not a formal TPP. Think of it as an internal whiteboard that asks: what would we need to prove to make this worth pursuing? A sound hypothesis document that is scoped correctly and built around your actual data is far more useful than a premature TPP for fundraising. This kind of hypothesis document is priced at a fraction of the cost of a formal TPP, without overstating the certainty of the science.
Phase 1:
This is the inflection point where a “TPP-lite” document earns its place. You likely have initial human PK/PD data, a preliminary safety signal, and enough evidence to anchor dose selection and endpoint discussions for the next study. The TPP-lite document should reflect the emerging data and explicitly delineate the minimum efficacy bar relative to existing therapies. It’s a genuine diligence asset for partnerships and out-licensing conversations, and the foundation for the regulatory strategy that will define your later clinical development (Phase 2 and/or Phase 3).
Phase 2:
This is where a full TPP can be worth the investment. Pivotal trial design, regulatory meeting strategy, commercial forecasting, and payer conversations all derive from it. This is also the last stage where significant pivots are survivable. TPP revisions here are far less costly than changes made after a pivotal trial is enrolled.
Regulatory, clinical, statistical, and commercial strategy teams can work directly from the TPP at this stage to design lean, efficient pivotal trials that maximize the probability of success without requiring a large-pharma-sized budget and ensure the right endpoints are in place to build product value for eventual divestiture or registration.
Related Reading: Why Separating Regulatory and Commercial Strategy Can Kill an Otherwise Promising Biotech
Phase 3 and NDA:
By this point, the TPP is largely formalized and fixed. The cost of revision is highest here, which is precisely why the TPP should have been carefully maintained, pressure-tested, and refined with tangible data obtained at the prior development stages.
TPP Alternatives for Early-Stage Product Developers
For companies not yet in the later stages of development, a formal TPP is often not the right tool. In fact, there are practical alternatives that accomplish the same strategic objectives:
Indication Prioritization Framework
A simple decision matrix scoring candidate indications on unmet need, competitive white space, regulatory precedent, and biological plausibility delivers most of the differentiation value of a TPP at a fraction of the cost. Many Facet clients use this with success as their working framework for early development.
Competitive Landscape and Hypothesis Document
A tightly scoped 10-15-page document focused on where your asset can outperform existing therapies and what data would be needed to support that claim is essential for the emerging biotech company. Facet’s regulatory and development experts build this with the FDA reviewer, payer, patient, sophisticated investor, and potential partner all in mind.
Key Assumptions Log
A living document tracking the three to five assumptions on which your program depends is a lean, low-overhead go/no-go mechanism. Facet uses a version of this internally when supporting asset valuation work for clients weighing whether to advance, pivot, or partner.
Asset Valuation Brief
For companies whose near-term goal is partnership or out-licensing rather than a full registration pathway, an asset valuation brief replaces the costly formal TPP. It translates your science into defensible product value for exactly the audience that matters most right now.
A Closer Look at What Works: Getting the Right Tool
How does this work in the real world? Let’s consider a three-person U.S. startup with a promising small molecule showing activity across multiple solid tumor indications, based on early tumor tissue data. They had friends and family money that enabled them to test the product in a variety of tumor tissues and complete one nonclinical rodent study. They were looking for investment to fund the required IND-enabling nonclinical studies and robust manufacturing (CMC) development to support a first-in-human trial under a U.S. IND.
The Challenge
The science was intriguing, but the company faced a question that trips up many early-stage biotechs: where do we focus when the biology points in several directions at once? Investors had already signaled that glioblastoma was not an attractive path given the competitive landscape, but that other solid tumor indications (e.g., breast cancer, NET disease) may be worth pursuing. That feedback, combined with their limited data package and Facet’s extensive oncology experience, gave Facet enough to work with.
The Solution
We built an indication prioritization framework to evaluate the solid tumor opportunities against unmet need, competitive white space, and what a three-person company could realistically execute. From that foundation, we developed a competitive landscape and hypothesis document that defined a differentiated nonclinical and CMC strategy. We paired this with a key assumptions log that established explicit go/no-go goalposts for the program.
The Result
Once completed, the biotech had a focused, executable plan built around real data. Importantly, the plan was on point and defensible in discussions with investors. No formal TPP was needed, and no premature commitments were made. Just a clear path forward that allowed them to secure additional funding!
The Facet Perspective: Traditional Development Models are Built for Large Pharma
The strategic clarity that a TPP provides is indispensable. The formal document is optional until the stakes of misalignment make it worth the investment. Knowing the difference between those two moments is exactly where the right regulatory and product development partner earns its value.
At Facet, we help small life science companies make those calls every day. Whether that means building a lean hypothesis document to support your Series A, developing a later-stage development TPP with regulatory precedent built into every attribute, or designing a clinical program that a small team can actually execute, we work alongside you as a true extension of your team, step by step, from early planning through submission.
Facet Life Sciences is a regulatory affairs and product development strategy partner for small biotech and emerging science companies. We guide you to and through the FDA — so you can get your products to patients in need.
gET sOCIAL